Powered by

Tris Pharma to Present Three Posters Covering Data on Dyanavel® XR and Tris' LiquiXR® Technology at the 2019 APSARD Annual Meeting

Jan 17, 2019 - PR Newswire

PR Newswire

 Tris Pharma, Inc. (Tris), a biopharmaceutical company focused on developing innovative products that deliver meaningful patient benefits, today announced that it will present information on its proprietary drug delivery platform LiquiXR® as well as data from two clinical studies on DYANAVEL XR (amphetamine) extended-release oral suspension, CII, at the 2019 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting held in Washington, D.C., January 1...